α-synuclein
α-Syn
α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.
α-synuclein Isoform Specific Products
All Product Categories
-
α-synuclein Inhibitors
(109)
View all products
-
α-synuclein Antagonists
(2)
View all products
-
α-synuclein Activator
(1)
View all products
-
α-synuclein Modulators
(2)
View all products
-
α-synuclein Inducers
(2)
View all products
-
α-synuclein Degraders
(11)
View all products
-
α-synuclein Control
(1)
View all products
-
α-synuclein Ligands
(6)
View all products
-
α-synuclein Related Products (149)
Related Products (149)
-
α-synuclein Isoform Comparison
-
Semaglutide-FITC
0 ImagesCat. No.: HY-114118F4Synonyms: Semaglutide-Lys(FITC)Semaglutide-FITC (Semaglutide-Lys(FITC)) is a fluorescent tracer probe (Ex/Em = 495/520 nm) obtained by covalently coupling the green fluorescent dye fluorescein isothiocyanate (FITC) (HY-66019) to the long-acting analogue of GLP-1, Semaglutide (HY-114118). Semaglutide-FITC can be used for studies on Semaglutide receptor binding (GLP-1R), cell uptake and endocytosis, in vivo tissue distribution, and the targeting efficiency of delivery systems.
-
PQQ-trimethylester
0 ImagesCat. No.: HY-160831CAS No.: 74447-88-4Synonyms: PQQ-TMEPQQ-trimethylester (PQQ-TME) is a synthetic compound that is a trimethylester derivative of pyrroloquinoline quinone (PQQ). PQQ-trimethylester has twice the blood-brain barrier permeability of PQQ (HY-100196) in vitro. In addition, PQQ-trimethylester shows strong inhibitory activity against α-synuclein, amyloid β1-42 (Aβ1-42) and prion protein fibrillation. PQQ-trimethylester can be used in the study of neurodegenerative diseases.
-
(S)-Minzasolmin
0 ImagesSynonyms: (S)-UCB0599; (S)-NPT200-11(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization.
-
Casanthranol
0 ImagesCasanthranol is a naturally derived, orally active mixture of anthraquinone glycosides that exhibits inhibitory activity against α-synuclein and bioactivities related to laxation. Casanthranol inhibits seed-induced α-synuclein fibrillation in cell-free systems and rescues preformed fibril-induced cytotoxicity in differentiated N2a cells. Casanthranol promotes intestinal transit in both the small and large intestines of mice with experimental constipation. Casanthranol can be used in research related to constipation.
-
MK-7337
0 ImagesMK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with 11C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination.
-
PBT434
0 ImagesSynonyms: ATH434PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD).
-
Semaglutide-d8 tetraTFA
0 ImagesCat. No.: HY-114118S1Purity: 99.84%Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
-
α-Synuclein inhibitor 10
0 Imagesα-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD).
-
Beta-asarone (Standard)
0 ImagesBeta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of α-synuclein, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases.
-
Hupehenine
0 ImagesHupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders.
-
α-Synuclein inhibitor 11
0 Imagesα-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research.
-
Cuminaldehyde (Standard)
0 ImagesCuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases.
-
LETC
0 ImagesLETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies.
-
tau Protein/α-synuclein-IN-1
0 ImagesCat. No.: HY-156435tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein-IN-1 can be used in study Alzheimer’s disease.
-
α-Synuclein (61-75) TFA
0 ImagesCat. No.: HY-P3140APurity: 99.32%α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
-
α-Synuclein 4554W
0 Imagesα-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease.
-
Peucedanocoumarin III
0 ImagesCat. No.: HY-122958CAS No.: 130464-57-2Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.
-
ELN484228
0 ImagesELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.
-
α-Synuclein (61-95) (human)
0 ImagesCat. No.: HY-P4704CAS No.: 154040-19-4α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
-
BTA-1_b
0 ImagesCat. No.: HY-151035CAS No.: 95856-73-8Synonyms: BTA-1-CH3BTA-1_b (BTA-1-CH3) is a structural analog of BTA-1 (HY-W278021). BTA-1 is an uncharged derivative of Thioflavin-T. It exhibits high affinity for Aβ fibrils and demonstrates excellent brain penetration and clearance capabilities.
